WHO HIVResNet HIV drug resistance laboratory operational framework - World Health Organization (WHO)

WHO HIVResNet HIV drug resistance laboratory operational framework  World Health Organization (WHO)

Women and HIV: Get the Facts on HIV Testing, Prevention, and Treatment - fda.gov

Women and HIV: Get the Facts on HIV Testing, Prevention, and Treatment  fda.gov

A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces th...

A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques  Nature

Some children who start antiretrovirals very early may control HIV after stopping treatment - Aid...

Some children who start antiretrovirals very early may control HIV after stopping treatment  Aidsmap

London patient remains HIV-free after 2.5 years off treatment - Aidsmap

London patient remains HIV-free after 2.5 years off treatment  Aidsmap

Scientists use gene-edited stem cells to treat HIV — with mixed success - Nature

Scientists use gene-edited stem cells to treat HIV — with mixed success  Nature

Nearly a third of babies with HIV given ART very soon after birth have no HIV antibodies two year...

Nearly a third of babies with HIV given ART very soon after birth have no HIV antibodies two years later  Aidsmap

Lenacapavir shows continued promise for first-line treatment and highly resistant HIV - Aidsmap

Lenacapavir shows continued promise for first-line treatment and highly resistant HIV  Aidsmap

‘Molecular scissors’ successfully remove HIV genes from all tissues in infected monkeys - Aidsmap

‘Molecular scissors’ successfully remove HIV genes from all tissues in infected monkeys  Aidsmap

Child with HIV maintains viral suppression for three years off treatment - Aidsmap

Child with HIV maintains viral suppression for three years off treatment  Aidsmap

Therapeutic vaccine shows potential for HIV control off treatment in early study - Aidsmap

Therapeutic vaccine shows potential for HIV control off treatment in early study  Aidsmap

Sharing anti-HIV medication is common in rural Uganda - Aidsmap

Sharing anti-HIV medication is common in rural Uganda  Aidsmap

New York woman is free of HIV 14 months after stem cell transplant - Aidsmap

New York woman is free of HIV 14 months after stem cell transplant  Aidsmap

Barcelona woman controls HIV for over 15 years without treatment - Aidsmap

Barcelona woman controls HIV for over 15 years without treatment  Aidsmap

São Paulo patient experiences apparent viral rebound a year and a half after stopping HIV treatme...

São Paulo patient experiences apparent viral rebound a year and a half after stopping HIV treatment  Aidsmap

One person remains undetectable without HIV drugs almost four years after using an antibody-based...

One person remains undetectable without HIV drugs almost four years after using an antibody-based therapy  Aidsmap

After viral rebound, dolutegravir-based treatment more likely to suppress HIV - Aidsmap

After viral rebound, dolutegravir-based treatment more likely to suppress HIV  Aidsmap

People with HIV gain weight faster than HIV-negative people - Aidsmap

People with HIV gain weight faster than HIV-negative people  Aidsmap

German man remains free of HIV nearly 10 years after stem cell transplant - Aidsmap

German man remains free of HIV nearly 10 years after stem cell transplant  Aidsmap

Oral lenacapavir can bridge gaps if injections must be missed - Aidsmap

Oral lenacapavir can bridge gaps if injections must be missed  Aidsmap

Brazilian man in long-term HIV remission – without a stem cell transplant - Aidsmap

Brazilian man in long-term HIV remission – without a stem cell transplant  Aidsmap

Long-acting capsid inhibitor GS-6207 confirms safety and antiviral activity - Aidsmap

Long-acting capsid inhibitor GS-6207 confirms safety and antiviral activity  Aidsmap

Can U=U be used to reshape HIV programmes globally? - Aidsmap

Can U=U be used to reshape HIV programmes globally?  Aidsmap

The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance be...

The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance become a problem?  Aidsmap

High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis - ...

High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis  ScienceDirect.com

HIV incidence fell by three-quarters in Australian gay men, with strong association with treatmen...

HIV incidence fell by three-quarters in Australian gay men, with strong association with treatment as prevention  Aidsmap

New cases of multi-drug resistant HIV becoming rarer in Europe - Aidsmap

New cases of multi-drug resistant HIV becoming rarer in Europe  Aidsmap

The amber light: the World Health Organization’s position when an HIV viral load is “suppressed b...

The amber light: the World Health Organization’s position when an HIV viral load is “suppressed but not undetectable”  Aidsmap

Biktarvy combination pill may be most effective option for people with HIV and hepatitis B - Aidsmap

Biktarvy combination pill may be most effective option for people with HIV and hepatitis B  Aidsmap

Have HIV-associated neurological disorders declined in people with HIV due to recent antiretrovir...

Have HIV-associated neurological disorders declined in people with HIV due to recent antiretrovirals?  Aidsmap

Yes, the same life expectancy as HIV-negative people, but far fewer years in good health - Aidsmap

Yes, the same life expectancy as HIV-negative people, but far fewer years in good health  Aidsmap

Earlier treatment and higher CD4 counts linked to smaller HIV reservoir - Aidsmap

Earlier treatment and higher CD4 counts linked to smaller HIV reservoir  Aidsmap

Intermittent dosing on HIV dual therapy leads to higher rate of treatment failure - Aidsmap

Intermittent dosing on HIV dual therapy leads to higher rate of treatment failure  Aidsmap

At-home support after HIV diagnosis in Uganda helps people get on ART and stick with it - Aidsmap

At-home support after HIV diagnosis in Uganda helps people get on ART and stick with it  Aidsmap

San Francisco shows that long-acting cabotegravir and rilpivirine may be feasible for people with...

San Francisco shows that long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression  Aidsmap

Broadly neutralising antibodies may be partners for long-acting antiretrovirals - Aidsmap

Broadly neutralising antibodies may be partners for long-acting antiretrovirals  Aidsmap

Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel? - Aidsmap

Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel?  Aidsmap

Two PEP doses spaced a week apart protect monkeys from injected HIV; one dose might work in human...

Two PEP doses spaced a week apart protect monkeys from injected HIV; one dose might work in humans  Aidsmap

Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing ...

Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing therapy  Aidsmap

Black MSM are 60% less likely to have suppressed HIV than white men in Atlanta - Aidsmap

Black MSM are 60% less likely to have suppressed HIV than white men in Atlanta  Aidsmap

HIV treatment in the womb helped five South African baby boys to stay undetectable off therapy - ...

HIV treatment in the womb helped five South African baby boys to stay undetectable off therapy  Aidsmap

Resistance testing does not improve viral suppression after first-line failure in South Africa an...

Resistance testing does not improve viral suppression after first-line failure in South Africa and Uganda  Aidsmap

Reduced-drug treatment becoming common in Paris - Aidsmap

Reduced-drug treatment becoming common in Paris  Aidsmap

PD-1 inhibitor budigalimab may delay viral rebound - Aidsmap

PD-1 inhibitor budigalimab may delay viral rebound  Aidsmap

More options for second-line treatment in children shown to be safe and effective - Aidsmap

More options for second-line treatment in children shown to be safe and effective  Aidsmap

Four days on, three days off HIV treatment as effective as continuous therapy, French study finds...

Four days on, three days off HIV treatment as effective as continuous therapy, French study finds  Aidsmap

Experts shed light on coronavirus response and its implications for people with HIV - Aidsmap

Experts shed light on coronavirus response and its implications for people with HIV  Aidsmap

Progress on 90-90-90 HIV targets shows stark gap between eastern and western Europe - Aidsmap

Progress on 90-90-90 HIV targets shows stark gap between eastern and western Europe  Aidsmap

Point-of-care viral load testing improves treatment outcomes and retention in care - Aidsmap

Point-of-care viral load testing improves treatment outcomes and retention in care  Aidsmap

“If we don’t include women in trials, we are not protecting women” – dolutegravir in pregnant wom...

“If we don’t include women in trials, we are not protecting women” – dolutegravir in pregnant women living with HIV  Aidsmap

Hepatitis C drops among HIV-positive London gay men after direct-acting antiviral scale-up - Aidsmap

Hepatitis C drops among HIV-positive London gay men after direct-acting antiviral scale-up  Aidsmap

The length of time Americans with HIV remain infectious is falling, but slowly - Aidsmap

The length of time Americans with HIV remain infectious is falling, but slowly  Aidsmap

African studies show that lowering viral load in the community reduces HIV incidence, but is not ...

African studies show that lowering viral load in the community reduces HIV incidence, but is not enough to eliminate HIV  Aidsmap

Fostemsavir salvage therapy continues to look good at 96 weeks - Aidsmap

Fostemsavir salvage therapy continues to look good at 96 weeks  Aidsmap

Long-acting injectables might be administered every two months - Aidsmap

Long-acting injectables might be administered every two months  Aidsmap

Islatravir plus doravirine maintains viral suppression for a year - Aidsmap

Islatravir plus doravirine maintains viral suppression for a year  Aidsmap

Woman with HIV with low CD4 count remained positive on SARS-CoV-2 tests for over 5 months - Aidsmap

Woman with HIV with low CD4 count remained positive on SARS-CoV-2 tests for over 5 months  Aidsmap

Who is at risk of injectable treatment failure? - Aidsmap

Who is at risk of injectable treatment failure?  Aidsmap

Adherence counselling reverses viral rebound on dolutegravir in 95% of cases - Aidsmap

Adherence counselling reverses viral rebound on dolutegravir in 95% of cases  Aidsmap

Luc Montagnier, co-discoverer of HIV, dies aged 89 - BBC

Luc Montagnier, co-discoverer of HIV, dies aged 89  BBC

Dolutegravir-based HIV treatment is the safest and most effective choice for pregnant women - Aid...

Dolutegravir-based HIV treatment is the safest and most effective choice for pregnant women  Aidsmap

Opportunistic infections remain common in people taking HIV treatment in Latin America - Aidsmap

Opportunistic infections remain common in people taking HIV treatment in Latin America  Aidsmap

Ibalizumab, active against highly resistant HIV, now approved in US - Aidsmap

Ibalizumab, active against highly resistant HIV, now approved in US  Aidsmap

Poor adherence associated with disruptive life events in young people living with HIV - Aidsmap

Poor adherence associated with disruptive life events in young people living with HIV  Aidsmap

Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option - Aidsmap

Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option  Aidsmap

Home tests aren’t an accurate way for people on HIV treatment to check they still have HIV - Aidsmap

Home tests aren’t an accurate way for people on HIV treatment to check they still have HIV  Aidsmap

Long-acting injectable treatment highly effective in European cohort studies - Aidsmap

Long-acting injectable treatment highly effective in European cohort studies  Aidsmap

Recycling tenofovir better than switch to second-line zidovudine - Aidsmap

Recycling tenofovir better than switch to second-line zidovudine  Aidsmap

Antiretroviral drug levels in hair strongly predict viral suppression - Aidsmap

Antiretroviral drug levels in hair strongly predict viral suppression  Aidsmap

Immune modulator clears pre-cancerous anal lesions - Aidsmap

Immune modulator clears pre-cancerous anal lesions  Aidsmap

Every-other-month injectable cabotegravir and rilpivirine suppresses viral load for two years - A...

Every-other-month injectable cabotegravir and rilpivirine suppresses viral load for two years  Aidsmap

Doravirine/islatravir just as effective as Biktarvy in previously untreated people - Aidsmap

Doravirine/islatravir just as effective as Biktarvy in previously untreated people  Aidsmap

Bictegravir safe and effective in pregnancy - Aidsmap

Bictegravir safe and effective in pregnancy  Aidsmap

Fact check: List of US patents is not evidence that viruses are manmade - Reuters

Fact check: List of US patents is not evidence that viruses are manmade  Reuters

Co-administration of dolutegravir-based treatment and short course of rifapentine/isoniazid (3HP)...

Co-administration of dolutegravir-based treatment and short course of rifapentine/isoniazid (3HP) well tolerated in people living with HIV  Aidsmap

Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence o...

Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence of resistance to recycled NRTIs  Aidsmap

COVID-19 pandemic has speeded up the implementation of multi-month dispensing - Aidsmap

COVID-19 pandemic has speeded up the implementation of multi-month dispensing  Aidsmap

Switching to Biktarvy maintains viral suppression in people aged 65 or over - Aidsmap

Switching to Biktarvy maintains viral suppression in people aged 65 or over  Aidsmap

Tenofovir (TDF) does not increase risk of kidney disease in people at low risk - Aidsmap

Tenofovir (TDF) does not increase risk of kidney disease in people at low risk  Aidsmap

Adolescent-centred interventions lead to a 30-percentage-point increase in viral suppression in N...

Adolescent-centred interventions lead to a 30-percentage-point increase in viral suppression in Namibia, and a 20-percentage-point increase in Nigeria  Aidsmap

Hepatitis C virtually eliminated in people with HIV in the Netherlands - Aidsmap

Hepatitis C virtually eliminated in people with HIV in the Netherlands  Aidsmap

Viral suppression in Uganda improved by more viral load tests, done faster - Aidsmap

Viral suppression in Uganda improved by more viral load tests, done faster  Aidsmap

Diagnosis and treatment for high blood pressure need to be funded as part of HIV treatment progra...

Diagnosis and treatment for high blood pressure need to be funded as part of HIV treatment programmes  Aidsmap

Fact check: COVID-19 is not a seasonal flu - Reuters

Fact check: COVID-19 is not a seasonal flu  Reuters

ヘンリー英王子とエルトン・ジョン、男性のエイズ対策で連携 - Reuters

ヘンリー英王子とエルトン・ジョン、男性のエイズ対策で連携  Reuters

アスクレティス・ファーマのIPOプレビュー：評価額を正当化するには、薬物による陶酔感が必要 - Smartkarma

アスクレティス・ファーマのIPOプレビュー：評価額を正当化するには、薬物による陶酔感が必要  Smartkarma